Nuveen Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-42,118
| Closed | -$221K | – | 3448 |
|
|
2024
Q1 | $221K | Sell |
42,118
-130,731
| -76% | -$685K | ﹤0.01% | 3166 |
|
|
2023
Q4 | $904K | Buy |
172,849
+30,147
| +21% | +$158K | ﹤0.01% | 2781 |
|
|
2023
Q3 | $2.25M | Buy |
142,702
+76,565
| +116% | +$1.21M | ﹤0.01% | 2254 |
|
|
2023
Q2 | $1.29M | Sell |
66,137
-24,685
| -27% | -$480K | ﹤0.01% | 2537 |
|
|
2023
Q1 | $2.58M | Buy |
90,822
+12,890
| +17% | +$366K | ﹤0.01% | 2237 |
|
|
2022
Q4 | $2.28M | Buy |
77,932
+13,013
| +20% | +$380K | ﹤0.01% | 2332 |
|
|
2022
Q3 | $1.72M | Sell |
64,919
-2,976
| -4% | -$78.6K | ﹤0.01% | 2478 |
|
|
2022
Q2 | $3.02M | Buy |
67,895
+25,859
| +62% | +$1.15M | ﹤0.01% | 2224 |
|
|
2022
Q1 | $2.06M | Buy |
42,036
+414
| +1% | +$20.3K | ﹤0.01% | 2490 |
|
|
2021
Q4 | $1.91M | Sell |
41,622
-6,026
| -13% | -$276K | ﹤0.01% | 2586 |
|
|
2021
Q3 | $2.66M | Sell |
47,648
-936
| -2% | -$52.2K | ﹤0.01% | 2539 |
|
|
2021
Q2 | $2.08M | Sell |
48,584
-4,159
| -8% | -$178K | ﹤0.01% | 2691 |
|
|
2021
Q1 | $2.2M | Buy |
52,743
+1,267
| +2% | +$52.9K | ﹤0.01% | 2575 |
|
|
2020
Q4 | $2.4M | Buy |
51,476
+1,795
| +4% | +$83.6K | ﹤0.01% | 2418 |
|
|
2020
Q3 | $2.11M | Sell |
49,681
-911
| -2% | -$38.7K | ﹤0.01% | 2357 |
|
|
2020
Q2 | $2.43M | Buy |
50,592
+6,276
| +14% | +$301K | ﹤0.01% | 2253 |
|
|
2020
Q1 | $2.04M | Buy |
44,316
+1,111
| +3% | +$51.1K | ﹤0.01% | 2176 |
|
|
2019
Q4 | $2.6M | Sell |
43,205
-533
| -1% | -$32K | ﹤0.01% | 2319 |
|
|
2019
Q3 | $2.47M | Sell |
43,738
-330
| -0.7% | -$18.7K | ﹤0.01% | 2312 |
|
|
2019
Q2 | $2.45M | Buy |
+44,068
| New | +$2.45M | ﹤0.01% | 2341 |
|